AHCO ADAPTHEALTH
Permanent stock page ↗Health Care · Russell 2000
Next earnings: not announced yet
What 9 analyst firms say about ADAPTHEALTH: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
7 rated views · 9 analyst/firm records · 9 firms
Radar score
- Russell 2000 · Top Picks · 6MBelow the Radar threshold of 8058
- Russell 2000 · Safest consensus · 6MBelow the Radar threshold of 8070
Recent analyst activity · last 90 days
Our tracked history has 4 reports on AHCO from 4 analyst firms in the last 90 days (9 firms in the past year).
Comparing each firm's latest target with its previous one: 1 raised its price target, 1 lowered it and 1 left it unchanged.
No firm's latest available rating differs from its previous one.
Latest observed target change: SVB Leerink raised its target from $7.00 (set 7 Aug 2026) to $8.00 on 5 Nov 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Baird | Eric Coldwell | Buy | 17 Sep 2026 | 9.00 USD |
| Canaccord Genuity | Richard Close | ConflictConflicting reports · excluded | 5 Aug 2026 | 10.00 USD |
| Jefferies | Brian Tanquilut | Buy | 21 Jul 2026 | Conflicting reports · excluded |
| Leerink Partners | Whit Mayo | Buy | 7 Aug 2026 | 7.00 USD |
| RBC Capital Markets | Ben Hendrix | Buy | 6 Aug 2026 | 8.00 USD |
| Truist | David MacDonald | Buy | 5 Aug 2026 | 9.00 USD |
| UBS | Kevin Caliendo | Buy | 6 Aug 2026 | 10.00 USD |
| Weiss Ratings | Unnamed analyst | — | 19 Aug 2026 | — |
| Data feed RESEARCH | Unnamed analyst | Hold | 1 Jan 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 06:12 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.